Big Breakthrough in the Battle Against Alzheimer’s
A Few Percentage Points That Might Change Everything
On September 27, Eisai Co Ltd and Biogen Inc announced that their experimental drug, lecanemab, finally beat the odds in one of the most litigious arenas in medicine. The study, involving 1,800 folks in the early stages of Alzheimer’s, found that lecanemab slowed cognitive and functional decline by 27 percent compared to a placebo. In plain English: If you’d expected a 100‑year wait, this could shave almost a third off the time the disease makes your loved ones lose their best memories.
“That’s a Positive Effect” – the researchers speak
Dr. Ronald Petersen of the Mayo Clinic’s Alzheimer’s Research Center summed up the sentiment: “It’s not a huge effect, but it’s a positive effect.” Suffice it to say that for families watching a beloved relative’s mind slowly wither, any positive shift is a weight lifted.
Next Steps: From Japan to the U.S.
- Eisai, which runs a 50‑50 partnership with Biogen on lecanemab, is pushing for an FDA accelerated review. The decision could come as early as January.
- He also plans a traditional FDA submission using the fresh efficacy data and intends to seek approval in Japan and Europe before the fiscal year ends on March 31.
Why This Matters
In the high‑stakes world of Alzheimer’s research, a drug’s success is often measured in dicey margins. Lecanemab’s performance tips the scale in favor of the amyloid hypothesis—the long‑held belief that clearing the sticky amyloid beta protein can slow disease progression. Dr. Petersen reflected: “This means that treating amyloid is a step in the right direction.”
The Stock Market Takes a Breath
Shares of Biogen and Eisai were momentarily halted, but Eli Lilly & Co, also developing an Alzheimer’s therapy, climbed as much as 6.7 percent in after‑hours trading. Trading desks now see lecanemab as “a potentially new multi‑billion dollar franchise,” according to Jefferies analyst Michael Yee.
Inside the Science: Not All “Amyloids” Are Equal
Lecanemab, like its predecessor Aduhelm, is an intravenous antibody that strips amyloid deposits. Where it shines is targeting early, un‑clumped amyloid—meant to catch the disease before it’s too deep in the brain’s fabric.
Dr. Jeff Cummings from the University of Nevada Las Vegas added, “If you can slow a disease by almost 30 percent that’s fantastic. This is what we have been looking for.”
Historical Context: The Crunchy Issue of Aduhelm
Aduhelm’s controversial 2021 FDA approval sparked debate because it focused on plaque removal rather than proven clinical benefit. The agency’s own advisory panel had advised against it, yet the drug got a green light, fueling skepticism about the amyloid approach.
Biogen’s latest result, however, brings a new narrative to the table – one that could change the FDA’s decision-making criteria.
Voices from the Frontlines
Patient advocates are buzzing. George Vradenburg, chairman of USAgainstAlzheimer’s, told Reuters, “This is important because it demonstrates that each of these drugs is different… I would hope that the FDA approves the drug in January.”
What the Phase III Trial Measured
The study assessed reductions in cognitive and functional decline using the Clinical Dementia Rating – Sum of Boxes (CDR‑SB): a numerical scale that evaluates memory, orientation, judgment, problem solving, and personal care. The drop in scores indicates that lecanemab doesn’t just look good on paper; it translates to real, measurable slowing of the disease.
In short, while this isn’t a cure‑all miracle, it’s a hopeful sign that the long‑standing fight against Alzheimer’s is getting a tangible foothold. For patients, families, and scientists alike, those 27 percent could bring a breath of fresh air into a journey that’s often defined by sorrow.
Brain swelling
What the Numbers Say About Lecanemab: A Quick Take on the Side‑Effect Snapshot
Brain Swelling – The Big Numbers
- All‑encompassing swelling: 12.5 % of patients taking lecanemab had any kind of brain puffiness, compared to only 1.7 % on placebo.
- Symptomatic swelling (the “real problem”): Just 2.8 % of lecanemab users actually felt the swelling – think of it as a small side hustle when it comes to symptoms.
Micro‑Hemorrhages – The Tiny Bleed Game
- In the lecanemab group, 17 % saw little brain hemorrhages.
- On placebo, the crowd was smaller: 8.7 %.
“Much Less Than Aduhelm,” Petersen Asserts
Dr. Petersen pointed out that these side‑effect rates are far below those seen with Aduhelm, calling them “certainly tolerable.” A win for the lecanemab camp, especially after Aduhelm’s pricing drama.
Recall: Aduhelm’s Price Sit‑Down
- Biogen slashed the price from $56,000 to $28,000 per year after criticism.
- But Medicare now insists that only patients participating in a valid clinical trial will get covered, meaning a steep drop in everyday use.
- Since Alzheimer’s mostly affects the over‑65 crowd, roughly 85 % of lecanemab patients could potentially qualify for Medicare coverage.
What’s Next for Lecanemab?
Michael Irizarry from Eisai said they’re planning talks with the Medicare agency to improve coverage. If successful, lecanemab might finally cross the silver gate many seniors rely on.
The Bigger Picture – Numbers that Grow
- In the U.S., Alzheimer’s patients are projected to climb from 6 million to about 13 million by 2050.
- Globally, the figure could hit 139 million by 2050 if we don’t find a solid cure.
Other Hopeful Players on the Court
- Roche’s gantenerumab
- Eli Lilly’s donanemab
Bottom line: Lecanemab shows a more favorable side‑effect profile than its predecessor, and the coming Medicare negotiations could decide if it gets the green light for widespread use.
